Mirum expands into liver diseases with Bluejay Therapeutics acquisition
Source: SeekingAlpha
2025-12-08 11:23:07 ET
More on Mirum Pharmaceuticals
- Mirum Pharmaceuticals, Inc. (MIRM) Presents at Evercore 8th Annual Healthcare Conference Transcript
- Mirum Pharmaceuticals, Inc. (MIRM) Q3 2025 Earnings Call Transcript
- Mirum aims for $500M–$510M 2025 revenue as cash flow turns positive and pivotal trial readouts approach
- Mirum Pharmaceuticals GAAP EPS of $0.05 beats by $0.19, revenue of $133M beats by $2.5M
- Seeking Alpha’s Quant Rating on Mirum Pharmaceuticals
Read the full article on Seeking Alpha
For further details see:
Mirum expands into liver diseases with Bluejay Therapeutics acquisition
Mirum Pharmaceuticals Inc.
NASDAQ: MIRM
MIRM Trading
1.3% G/L:
$90.695 Last:
250,112 Volume:
$89.85 Open:
MIRM Latest News
March 05, 2026 08:00:00 am
Mirum Pharmaceuticals Provides AZURE Clinical Program Update for brelovitug in Chronic Hepatitis Delta Virus
MIRM Stock Data
$5,184,583,745
44,013,457
0.43%
119
N/A
Biotechnology & Life Sciences
Healthcare
US
Foster City
